REL RELX PLC

China's Healthcare Market to See Surge of Investment and Opportunities in Next 15 Years

SHANGHAI--(BUSINESS WIRE)--

Last October, the Chinese government approved a blueprint called “Healthy China 2030”, pledging to build a healthy China in the next 15 years. By 2030, the size of the healthcare market is expected to reach $2.3 trillion. This initiative is in line with China’s determination to deepen the supply-side structural reforms in 2017 by substantially driving down overcapacity, and increasing efficient supply which call for stricter standards in healthcare industry. The next 15 years will see a surge of investment and changes in the industry.

Healthcare China 2017, organized by Reed Sinopharm Exhibitions (RSE), is a platform for global investors to discover more about the dynamics of healthcare business in China. To be held on May 13-14, 2017, at the Pullman Shanghai, the event will attract corporate leaders, government regulators, influencers, researchers and entrepreneurs, focusing on three main areas of investors’ interest—biomedical, medical devices, and medical services.

SURGING POTENTIAL

China’s healthcare market is projected to grow at an unprecedented CAGR of about 12% to reach $1 trillion by 2020, up from $357 billion in 2011, as estimated in a recent report from McKinsey & Co. Against the backdrop of key technological changes such as artificial intelligence, Healthcare China 2017 will invite the principal of IBM Watson to deliver a speech on “The Future of Artificial Intelligence in Medical Industry”. Besides, industrial experts will discuss market trends and analyse government programs aiming to promote a tiered healthcare system, ensure effective drug delivery and management.

PROMOTING INTERNATIONAL PARTNERSHIP

China’s healthcare sector has been attracting increasing investment from global investors who are keen on entering or expanding their presence in China. Healthcare China 2017, which features the Top 60 innovative healthcare companies in China today, and profiles at least 500 influential CEOs and partners of leading investment companies, will be a place for global healthcare companies to demonstrate their product and process excellence, and learn China’s regulations and policies in the industry.

To register and know more about the event, visit http://www.thishealthsummit.com/

EN
27/03/2017

Underlying

RELRELX PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RELX PLC

ING Helpdesk
  • ING Helpdesk
REL RELX PLC
SBMO SBM OFFSHORE NV ... (+6)

Benelux Morning Notes

CTP: Good results, continuation of strong demand dynamics. KBC: 2025 outlook, strong uplift post 2Q. RELX, Wolters Kluwer: Thomson Reuters 2Q25 results. SBM Offshore: Guidance up, one-offs play a role. Xior Student Housing: On track, continued focus on pricing and pipeline

REL RELX PLC
SBMO SBM OFFSHORE NV
KBC KBC GROUP N.V.
WKL WOLTERS KLUWER NV
XIOR XIOR STUDENT HOUSING N.V.
CTPNV CTP NV
08/07/25 August 7, 2025 1 EN
David Vagman ... (+5)
  • David Vagman
  • CFA
  • Marc Hesselink
  • CFA
  • Thymen Rundberg
REL RELX PLC

RELX/Onward and upward/BUY

RELX delivered a solid 1H25 performance in our view. The business mix continues to shift towards higher growth data analytics and decision tools across all divisions, resulting in good organic revenue growth and operating leverage, broadly in line with our expectations. As a result, we make only slight adjustments to our growth and margin estimates. We reiterate our BUY rating and lower our target price to €56 per share (from €57), mainly due to FX headwinds.

08/05/25 August 5, 2025 1 EN
Jan Frederik Slijkerman
  • Jan Frederik Slijkerman
REL RELX PLC

RELX grows faster than telcos/Company exhibits strong credit metrics

RELX continued its strong performance over 1H25. We appreciate its strong growth profile and healthy balance sheet. We expect the company to maintain A- ratings and therefore prefer the RELX notes over the notes of telecom operators with a BBB+ rating, such as Orange or Verizon.

07/24/25 July 24, 2025 1 EN
Jan Frederik Slijkerman ... (+5)
  • Jan Frederik Slijkerman
  • Jeroen van den Broek
  • Jesse Norcross
  • Nadège Tillier
  • Timothy Rahill
EUR 85.95
REL RELX PLC

Coffee, Croissants & Credit/IBM, RELX

IBM reports solid figures, but growth is not accelerating as we see elsewhere. RELX reports strong 1H25 results

07/24/25 July 24, 2025 1 EN
ING Helpdesk
  • ING Helpdesk
REL RELX PLC
BAMNB Koninklijke BAM... ... (+8)

Benelux Morning Notes

Aalberts: Light 1H performance, lowers FY25 outlook. Acomo: Hot chocolate. BAM Group: Solid 1H25 performance. BE Semiconductor Industries: 2Q25 results, light at the end of the tunnel. Econocom: 1H25 REBITA in line, net profit hit by €18m loss on discontinued. Orange Belgium: Better 1H25, guidance increased but MSA hurt perception. RELX: 1H25 results – powering ahead. UCB: 1H25 Preview: focus on US expansion.

REL RELX PLC
BAMNB KONINKLIJKE BAM GROEP NV
UCB UCB S.A.
ACOMO AMSTERDAM COMMODITIES N.V.
AALB AALBERTS N.V.
ECONT ECONOCOM GROUP SE CLASS D
OBEL ORANGE BELGIUM SA
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
07/24/25 July 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch